Sep / 2025

OncoDaily IO OncoDaily GI Hemostasis Today

Apr 27, 2024 7:10 am

Apr 26, 2024 8:26 pm

Apr 26, 2024 3:34 pm

Apr 26, 2024 3:15 pm

Apr 26, 2024 2:53 pm

Apr 26, 2024 2:15 pm

Apr 26, 2024 1:58 pm

Apr 26, 2024 1:29 pm

Apr 26, 2024 11:17 am

Apr 25, 2024 8:18 pm

…

551

…

Benjamin Diamond: Our paper on genomic profiling of high-risk smouldering myeloma now in Clinical Cancer Research

New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial

A Case Study of Metastatic Paraganglioma with Álvaro Lopes de Oliveira

Aaron Goodman: I will be hosting the myeloma session with some legends in the field

Cristiane Bergerot: Grateful to receive a heartwarming email from ⁦ASCO, thanking me for my contributions during Global Volunteer Month

Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Common Sense Oncology leadership team is having its first annual meeting in Montreal

Mark Lewis: How one of my patients described chemo cycles and oh my

Satya Prakash Yadav: Europe in 2022 BMT and Cell Therapy trends

Vivek Subbiah: HUGE MILESTONE in all of medicine and a huge win for patients and families with sickle cell disease and β-Thalassemia

Headlines

Benjamin Diamond: Our paper on genomic profiling of high-risk smouldering myeloma now in Clinical Cancer Research

New Paper Alert! Liposomal Irinotecan vs Topotecan for Relapsed Small Cell Lung Cancer: RESILIENT Phase 3 Trial

A Case Study of Metastatic Paraganglioma with Álvaro Lopes de Oliveira

Aaron Goodman: I will be hosting the myeloma session with some legends in the field

Cristiane Bergerot: Grateful to receive a heartwarming email from ⁦ASCO, thanking me for my contributions during Global Volunteer Month

Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Common Sense Oncology leadership team is having its first annual meeting in Montreal

Mark Lewis: How one of my patients described chemo cycles and oh my

Satya Prakash Yadav: Europe in 2022 BMT and Cell Therapy trends

Vivek Subbiah: HUGE MILESTONE in all of medicine and a huge win for patients and families with sickle cell disease and β-Thalassemia

Headlines

OncoDaily

Oncology

cancer

fight against cancer

Global fight against cancer

cancer care

Breast Cancer

ASCO

Lung cancer

Cancer research

MD Anderson Cancer Center

cancer awareness

NSCLC

ESMO

immunotherapy

cancer treatment

Research

ASCO24

Headlines

colorectal cancer

Childhood Cancer

prostate cancer

AACR

clinical trials

FDA

Dana-Farber Cancer Institute

UICC

American Cancer Society

European Cancer Organisation

NCI

National Cancer Institute

healthcare

SIOP

ASCO25

chemotherapy

Vivek Subbiah

AI

American Society of Clinical Oncology

Paolo Tarantino

IASLC

WHO

Robert Orlowski

multiple myeloma

Memorial Sloan Kettering Cancer Center

Zainab Shinkafi-Bagudu

radiation oncology

Myeloma Paper of the Day

cervical cancer

Myeloma

patient care

European School of Oncology

Sitemap